Table 2.
Demographic and clinical features of the previously published cases of rash associated with antipsychotics
| Variables | Total (N = 172) | Total (%) | Mean |
|---|---|---|---|
| Sex | |||
| Female | 83 | 48.26 | |
| Male | 89 | 51.74 | |
| Age | 34.29 (N = 163) | ||
| ≥ 60 years | 13 | 7.56 | |
| ≥ 18 years, < 60 years | 138 | 80.23 | |
| < 18 years | 12 | 6.98 | |
| ND | 9 | 5.23 | |
| Second-generation antipsychotics | |||
| Amisulpride | 3 | 1.74 | |
| Aripiprazole | 12 | 6.98 | |
| Clozapine | 42 | 24.42 | |
| Lurasidone | 2 | 1.16 | |
| Olanzapine | 14 | 8.14 | |
| Paliperidone | 3 | 1.74 | |
| Perospirone | 1 | 0.58 | |
| Quetiapine | 14 | 8.14 | |
| Risperidone | 25 | 14.53 | |
| Ziprasidone | 2 | 1.16 | |
| First-generation antipsychotics | |||
| Chlorpromazine | 25 | 14.53 | |
| Haloperidol | 13 | 7.56 | |
| Perphenazine | 3 | 1.74 | |
| Sulpiride | 13 | 7.56 | |
| Tiapride | 1 | 0.58 | |
| Zuclopenthixol | 1 | 0.58 | |
ND, information not described